Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 Stocks With Monster Returns. Travere Therapeutics grew its share ...

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 Overlooked Growth Stocks to Buy Now. Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the overlooked growth stocks to buy now. On April 13, ...

With the path to blockbusterland now in sight, Travere Therapeutics is ready to hit the ground running after Monday’s ...

Travere Therapeutics (TVTX) shares soared 37.2% in the last trading session to close at $42.13. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Yet, the company has defied the odds, securing Filspari a landmark FDA approval in focal segmental glomerulosclerosis (FSGS) ...

The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis ...

Travere Therapeutics has received the US Food and Drug Administration (FDA) full approval for Filspari (sparsentan) to reduce ...

FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure Ligand is ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

The trial compares sparsentan, an oral pill developed by Travere Therapeutics, Inc., with the standard angiotensin receptor blocker irbesartan. Both drugs aim to slow kidney damage in focal segmental ...

Shrugging off an earlier phase 3 disappointment, Travere’s Filspari has become the first FDA-approved treatment for rare ...

Notably, investors poured funds into industries with promising growth prospects, namely semiconductor and quantum computing, ...